



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Feedback from the Global Fund Meeting with Manufacturers of ACTs

2 November 2011

Sophie Logez
Pharmaceutical Management Unit

Objectives of the meeting

- Provide an update on Global Fund policies and processes on procurement and supply management
 - Policies, Quality assurance
 - Procurement information: price and Quality
 - Market shaping strategy and Voluntary Pooled Procurement
 - AMFm overview
- Dialogue with manufacturers
 - Feedback
 - Procurement challenges

1. Grants approved by Board for malaria = \$6.1 billion – 84 countries [plan] (2002-2011: rounds 1-10)


2. Treatment = 28% malaria grants expenditure (2009 data)

3. Global Fund public sector ACT volumes

- **Historic delivery data [PQR + estimate of non-reported]**
 - 2009: 80-90 million courses
 - 2010: 85-105 million courses
- **Estimate**
 - 2011: 90-105 million courses
 - *2012-2013: 100 million + courses per year*

Value of antimalarial medicines reported as procured in 2010 and 2011YTD (PQR data)

Total product value reported: 66.9 million US\$



Better defining & managing Procurement and Supply Management (PSM) risks

- Increased oversight of PSM activities and risks
- Investments in PSM systems encouraged
- Voluntary Pooled Procurement mechanism (VPP): a tool to improve grant performance; mitigate risk (financial and treatment disruption); and to influence market dynamics

Proposed/planned

- Identify necessary policy changes to fully implement VPP
- Responding to stock outs: financial & physical buffer stock
- More actively shape markets to optimize price, quality, design, & sustainable supply

Quality Assurance Policy for Pharmaceutical Products

Clinical Criteria

Medicines listed in WHO or national or institutional Standard Treatment Guidelines

Quality Criteria

- **For all products:**
Authorized for use in recipient countries
- **For ARVs, anti-TB and anti-malarial products:**
WHO Prequalified or authorized by a Stringent Regulatory Authorities; **OR** Recommended for use by **Expert Review Panel**

Monitoring Quality

- Monitoring quality of products all along the supply chain
- Systematic random quality control testing
- Recipients report testing results to Global Fund

The Expert Review Panel


- A panel of experts to assess the potential risks/benefits with the use of finished products not yet WHO-prequalified or SRA-authorized
 - assess products dossier submitted by manufacturers
- a one-off review
- Time limited recommendations: validity 12 months
- Products permitted for use listed on the Global Fund the website
- At PR request, a product can be reviewed by the ERP for a specific context
- Minimum condition: manufacturing site of the product must be GMP compliant.

Expediting transition to fixed-dose combinations

- Fixed-dose combinations of ACTs strongly recommended by WHO
- 2 combinations affected: ASAQ* and ASMQ*

“The Board determines that once the Secretariat has decided in its discretion that there are at least 2 FDC Finished Pharmaceutical Products of an ACT Formulation for the treatment of uncomplicated malaria that comply with the Global Fund QA Policy and each FDC ACT is considered “available”,
...The Secretariat, in collaboration with partners, will facilitate the provision of support to recipients of Global Fund financing to conduct an effective and timely transition to FDC ACTs where necessary and appropriate.”

Reporting prices and quality



Home > Procurement and Supply Management > Price & Quality Reporting (PQR)

Home

Guide to Writing PSM Plans

Quality Assurance Information

Price and Quality Reporting

Procurement Support Services

Information for Suppliers

PRICE AND QUALITY REPORTING

The Price and Quality Reporting (PQR) Tool is a web-based system used by the Global Fund to collect transaction level procurement information from Principal Recipients on key health products. The system's goals are to:

| Report | Description |
|---------------------------------|---|
| Regional Price Reference | View the prices that other Principal Recipients are paying for a product in your region |
| Grant Report | Compare the prices that you paid against a median. Highlights potential savings. |
| Transaction Search | View a subset of transactions or download all transactions for further analysis. |

External Links

Log into the PQR

Related Documents

PQR FAQ
(PDF - 218 KB)

Additional Languages

PQR Quick Guide
(PDF - 1 MB)

Additional Languages

Hanoi, 2 November 2011

The use of the comparative data

1. Informing budgets
2. Monitoring efficiencies

VIEW PRICES BY REGION

SELECT A REGION (optional)
 Eastern Europe & Central Asia

SELECT PRODUCT NAME
 Abacavir (ABC)

SELECT STRENGTH
 300mg

Go

| Country or Territory | Grant | Manufacturer | Supplier / Agent / Intermediary | Purchase Order Date | Total Package Quantity | Product Pack | Unit Cost (USD) ▲ | Pack Cost (USD) |
|----------------------|------------------|-------------------------|--|---------------------|------------------------|------------------|-------------------|-----------------|
| Armenia | ARM-202-G05-H-00 | Aurobindo Pharma Ltd | VPP, through Partnership for Supply Chain Management (PFSCM) | 03-Sep-2010 | 103 | Bottle of 60 tab | \$0.26 | \$15.50 |
| Georgia | GEO-S10-G07-H | Aurobindo Pharma Ltd | Partnership for Supply Chain Management Inc (PFSCM) | 27-Oct-2010 | 4,216 | Bottle of 60 tab | \$0.26 | \$15.50 |
| Belarus | BLR-809-G03-H | Cipla Ltd | UNICEF Supply Division | 14-May-2010 | 5,542 | Bottle of 60 tab | \$0.28 | \$16.90 |
| Uzbekistan | UZB-304-G01-H | Cipla Ltd | UNICEF Supply Division | 12-Mar-2010 | 1,050 | Bottle of 60 tab | \$0.28 | \$16.90 |
| Albania | ALB-506-G01-H | Matrix Laboratories Ltd | UNICEF Supply Division | | | | | |
| Uzbekistan | UZB-304-G01-H | Matrix Laboratories Ltd | UNICEF Supply Division | | | | | |
| Moldova | MOL-607-G03-H | Matrix Laboratories Ltd | IDA Foundation | | | | | |

Available online Reports – View Best Prices by Region

Hanoi, 2 November 2011

Help Needed

1. Notify us if you find any discrepancies in the data
2. Review the product master lists to be provided
 - Confirm pack sizes, manufacturing sites, and WHO/SRA approval dates
 - Inform us of any missing products or data
3. Add key information often missing on invoices:
 - **Manufacturing Site:** Needed to confirm approvals
 - **Comparable Prices:** Breakout freight and insurance